BLUEPRINT MEDICINES CORPORATION Financials Blueprint Medicines Corporation
Equities
BPMC
US09627Y1091
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93 USD | +2.50% |
|
+7.08% | +0.82% |
| Apr. 25 | Transcript : Blueprint Medicines Corporation - Special Call | |
| Mar. 22 | Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,942 | 6,250 | 6,302 | 2,621 | 5,607 | 5,842 | - | - |
| Enterprise Value (EV) 1 | 3,458 | 5,378 | 5,825 | 1,815 | 5,135 | 5,713 | 5,803 | 5,705 |
| P/E ratio | -11 x | 20.1 x | -9.73 x | -4.69 x | -11 x | -16.8 x | -36.1 x | 219 x |
| Yield | - | - | - | - | - | - | 1.08% | 1.08% |
| Capitalization / Revenue | 59.3 x | 7.87 x | 35 x | 12.8 x | 22.5 x | 14.9 x | 9.75 x | 7.11 x |
| EV / Revenue | 52 x | 6.78 x | 32.3 x | 8.9 x | 20.6 x | 14.5 x | 9.68 x | 6.94 x |
| EV / EBITDA | -9.71 x | 17.1 x | -9.17 x | -3.45 x | -10.8 x | -16.7 x | -37.9 x | 798 x |
| EV / FCF | -11.8 x | 14 x | -19.3 x | -3.55 x | -11.3 x | -21.8 x | -91.6 x | 46.8 x |
| FCF Yield | -8.44% | 7.14% | -5.18% | -28.2% | -8.82% | -4.59% | -1.09% | 2.14% |
| Price to Book | 8.5 x | 4.41 x | 6.53 x | 5.1 x | 43.2 x | -87.7 x | -47.4 x | -59.2 x |
| Nbr of stocks (in thousands) | 49,202 | 55,731 | 58,838 | 59,831 | 60,790 | 62,815 | - | - |
| Reference price 2 | 80.11 | 112.2 | 107.1 | 43.81 | 92.24 | 93.00 | 93.00 | 93.00 |
| Announcement Date | 2/13/20 | 2/17/21 | 2/16/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 66.51 | 793.7 | 180.1 | 204 | 249.4 | 393 | 599.4 | 822.2 |
| EBITDA 1 | -356.1 | 315.3 | -635.5 | -525.8 | -474.6 | -341.9 | -153 | 7.147 |
| EBIT 1 | -361.3 | 308.7 | -642 | -537.5 | -486.3 | -313 | -120.3 | 74.28 |
| Operating Margin | -543.25% | 38.89% | -356.5% | -263.44% | -194.99% | -79.63% | -20.08% | 9.03% |
| Earnings before Tax (EBT) 1 | -347.7 | 314.9 | -641.1 | -552.3 | -506 | -342.5 | -156.7 | 16.88 |
| Net income 1 | -347.7 | 313.9 | -644.1 | -557.5 | -507 | -340.1 | -160.6 | 22.56 |
| Net margin | -522.75% | 39.54% | -357.67% | -273.24% | -203.3% | -86.53% | -26.79% | 2.74% |
| EPS 2 | -7.270 | 5.590 | -11.01 | -9.350 | -8.370 | -5.544 | -2.576 | 0.4250 |
| Free Cash Flow 1 | -292 | 383.9 | -301.7 | -511.2 | -452.9 | -262.3 | -63.38 | 122 |
| FCF margin | -439.06% | 48.36% | -167.56% | -250.54% | -181.61% | -66.74% | -10.57% | 14.84% |
| FCF Conversion (EBITDA) | - | 121.76% | - | - | - | - | - | 1,706.71% |
| FCF Conversion (Net income) | - | 122.3% | - | - | - | - | - | 540.72% |
| Dividend per Share 2 | - | - | - | - | - | - | 1.000 | 1.000 |
| Announcement Date | 2/13/20 | 2/17/21 | 2/16/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 24.19 | 107 | 62.73 | 36.55 | 65.98 | 38.78 | 63.29 | 57.57 | 56.57 | 71.96 | 81.44 | 93.07 | 104.3 | 115.5 | 121 |
| EBITDA 1 | -115.5 | -314.5 | -104.2 | -156.2 | -122.7 | -142.8 | -120.5 | -124.4 | -126.1 | -103.6 | -95 | -89 | -83 | -81 | -61 |
| EBIT 1 | -117.1 | -316.1 | -105.8 | -157.6 | -124.3 | -149.8 | -124.2 | -128 | -129 | -105.1 | -94.65 | -83.5 | -71.08 | -59.77 | -61.95 |
| Operating Margin | -484.11% | -295.39% | -168.66% | -431.33% | -188.36% | -386.27% | -196.26% | -222.31% | -228.02% | -146.07% | -116.22% | -89.72% | -68.15% | -51.73% | -51.19% |
| Earnings before Tax (EBT) 1 | -117.1 | -316.1 | -105.8 | -156.6 | -132.3 | -157.6 | -129 | -132.6 | -133.5 | -110.9 | -101.3 | -91 | -79.9 | -70.24 | -72.57 |
| Net income 1 | -117.2 | -318.7 | -106 | -159.7 | -133.2 | -158.6 | -129.6 | -132.8 | -133.7 | -110.9 | -101.1 | -90 | -79.39 | -69.67 | -68.71 |
| Net margin | -484.71% | -297.78% | -168.97% | -437% | -201.83% | -409.06% | -204.72% | -230.66% | -236.38% | -154.14% | -124.1% | -96.7% | -76.12% | -60.3% | -56.78% |
| EPS 2 | -2.000 | -5.400 | -1.790 | -2.680 | -2.230 | -2.650 | -2.150 | -2.190 | -2.200 | -1.820 | -1.648 | -1.456 | -1.275 | -1.102 | -1.055 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/28/21 | 2/16/22 | 5/3/22 | 8/2/22 | 11/1/22 | 2/16/23 | 5/4/23 | 8/2/23 | 10/26/23 | 2/15/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 484 | 872 | 477 | 806 | 472 | 129 | 38.3 | 136 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -292 | 384 | -302 | -511 | -453 | -262 | -63.4 | 122 |
| ROE (net income / shareholders' equity) | -78.7% | 32.5% | -52.8% | -75.1% | -157% | - | - | - |
| ROA (Net income/ Total Assets) | -55.7% | - | - | - | - | - | - | - |
| Assets 1 | 623.9 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 9.420 | 25.40 | 16.40 | 8.580 | 2.140 | -1.060 | -1.960 | -1.570 |
| Cash Flow per Share | -5.810 | - | - | - | - | - | - | - |
| Capex 1 | 14 | 3.16 | 3.09 | 8.92 | 16.1 | 12.1 | 12 | 11.9 |
| Capex / Sales | 21.07% | 0.4% | 1.72% | 4.37% | 6.44% | 3.08% | 2% | 1.45% |
| Announcement Date | 2/13/20 | 2/17/21 | 2/16/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
93
USD
Average target price
98.06
USD
Spread / Average Target
+5.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.82% | 5.84B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BPMC Stock
- Financials Blueprint Medicines Corporation
